- Home
- ANL vs HLVX Comparison
ANL vs HLVX Comparison
Compare ANL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- HLVX
- Stock Information
- Founded
- ANL 2004
- HLVX 2020
- Country
- ANL Cayman Islands
- HLVX United States
- Employees
- ANL N/A
- HLVX N/A
- Industry
- ANL
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- HLVX Health Care
- Exchange
- ANL Nasdaq
- HLVX Nasdaq
- Market Cap
- ANL 73.8M
- HLVX 83.7M
- IPO Year
- ANL 2023
- HLVX 2022
- Fundamental
- Price
- ANL $1.80
- HLVX $1.93
- Analyst Decision
- ANL Strong Buy
- HLVX Hold
- Analyst Count
- ANL 2
- HLVX 5
- Target Price
- ANL $9.00
- HLVX $2.33
- AVG Volume (30 Days)
- ANL 10.1K
- HLVX 219.8K
- Earning Date
- ANL 06-10-2025
- HLVX 05-08-2025
- Dividend Yield
- ANL N/A
- HLVX N/A
- EPS Growth
- ANL N/A
- HLVX N/A
- EPS
- ANL N/A
- HLVX N/A
- Revenue
- ANL N/A
- HLVX N/A
- Revenue This Year
- ANL N/A
- HLVX N/A
- Revenue Next Year
- ANL N/A
- HLVX N/A
- P/E Ratio
- ANL N/A
- HLVX N/A
- Revenue Growth
- ANL N/A
- HLVX N/A
- 52 Week Low
- ANL $1.10
- HLVX $1.34
- 52 Week High
- ANL $8.88
- HLVX $15.60
- Technical
- Relative Strength Index (RSI)
- ANL 42.48
- HLVX 51.02
- Support Level
- ANL $1.71
- HLVX $1.82
- Resistance Level
- ANL $2.10
- HLVX $1.89
- Average True Range (ATR)
- ANL 0.08
- HLVX 0.07
- MACD
- ANL 0.00
- HLVX -0.02
- Stochastic Oscillator
- ANL 0.00
- HLVX 22.73
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.